GSK Argues Its Strategy Is Delivering As It Makes More Cuts, Including In R&D
Executive Summary
GlaxoSmithKline CEO Andrew Witty declared on Feb. 4 that his strategy of building a global, diversified business was delivering. And to prove his point, he announced a return to full-year sales growth in 2009 after a negative 2008, and an upbeat forecast for 2010 as well
You may also be interested in...
Axovant Builds A Case For GSK’s 5-HT6 Castoff In Alzheimer’s
Latest data suggest startup Axovant has a plausible path for its modestly effective RVT-101 toward approval, but the field is still inherently risky and the market is wary nevertheless.
GSK Pays $31.5 Million Upfront, Plus Milestones To Access Angiochem’s Rare Disease Technologies
GlaxoSmithKline takes aim at neurological symptoms of lysosomal storage diseases, increasing likely future competitive pressure on Sanofi's and Shire's rare disease products.
Prospects For GSK/XenoPort's Horizant Sink After Rejection By FDA
An FDA "complete response" letter for the modified gabapentin formula surprised Wall Street, raising questions about similar drugs in development.